Searchable abstracts of presentations at key conferences in endocrinology

ea0013s1 | Society for Endocrinology Dale Medal Lecture | SFEBES2007

The ever expanding role of somatostatin receptors in endocrine disease

Lamberts Steven WJ , Hofland Leo J

Studies on the distribution of Somatostatin Receptor (sst)-subtypes on endocrine tumors, the development of sst-subtype specific analogues, the elucidation of phenomena like receptor desensitization and ligand-receptor internalization, and the potential consequences (and reversal) of the epigenetic silencing of sst offer new diagnostic and therapeutic modalities in endocrine diseases:1. apart from sst2 activation, Somatostatin analogues target...

ea0016p395 | Neuroendocrinology | ECE2008

Dopamine receptor expression and dopamine agonist effectiveness in corticotroph pituitary tumors: comparison with clinical, biochemical radiological and pathological features of patients with Cushing's disease

Pivonello Rosario , de Herder Wouter W , Ferone Diego , Kros Johan M , De Caro Maria Laura Del Basso , Lombardi Gaetano , Colao Annamaria , Hofland Leo J , Lamberts Steven WJ

Dopamine receptors (DR) are expressed in the majority of corticotroph pituitary tumors and the dopamine agonist cabergoline is effective in controlling cortisol hypersecretion in around 50% of patients with Cushing’s disease (CD). In order to characterize the tumors expressing D2 receptors and the profile of patients which might respond to the treatment with D2 agonists, the current study has the aim to correlate D2 receptor expression and...

ea0014p142 | (1) | ECE2007

Dopamine receptor expression and dopamine agonist effectiveness in post-surgical persistent medullary thyroid cancer

Pivonello Rosario , Ferolla Piero , Faggiano Antongiulio , Ferone Diego , Cerasola Enrica , Angeletti Gabriella , Santeusanio Fausto , Minuto Francesco , Lombardi Gaetano , Lamberts Steven WJ , Hofland Leo J , Colao Annamaria

Dopamine receptors was suggested to be expressed in medullary thyroid cancer (MTC). The aim of the current study was to evaluate the expression of D2 dopamine receptor in MTC and the effectiveness of the dopamine agonist cabergoline in patients with MTC. Five paraffin-embedded cases of MTC obtained after thyroidectomy were used to evaluate D2 receptor expression by immunohistochemistry. Fifteen patients (7 males, 8 females, 36–78 years) with post-sur...

ea0014p558 | (1) | ECE2007

Cabergoline treatment in Cushing’s disease: effect on hypertension, glucose intolerance and dyslipidemia.

Pivonello Rosario , Martino Maria Cristina De , Faggiano Antongiulio , Leo Monica De , Lombardi Gaetano , Hofland Leo J , Lamberts Steven WJ , Colao Annamaria

Cabergoline has been recently demonstrated to normalize cortisol secretion in more than one third of patients with Cushing’s disease (CD). The aim of this study was to evaluate short-term (3-months) and long-term (12-24 months) effects of cabergoline treatment on the main systemic complications of CD, including hypertension, glucose intolerance and dyslipidemia. Twenty patients with CD unsuccessfully treated by neurosurgery entered the study. Cabergoline was admistered at...

ea0014p559 | (1) | ECE2007

Development and validation of a questionnaire to evaluate health-related quality of life in patients with Cushing’s syndrome

Webb Susan M , Badia Xavier , Barahona Maria- Jose , Colao Annamaria , Strasburger Christian J , Tabarin Antoine , Aken MO van , Pivonello Rosario , Stalla Gunther , Chabre O , Lamberts Steven WJ , Glusman Joan E

Chronic exposure to hypercortisolism has a significant impact on patient’s health and Health-Related Quality of Life (HRQoL), as demonstrated with generic questionnaires. Objective: Develop and validate a disease-generated questionnaire to evaluate HRQoL in patients with Cushing’s syndrome-CS- (Cushing QoL). Methods: After a literature review, interviews with expert endocrinologists and 10 patients identified HRQoL domains and clinical aspects of the disease; an anal...

ea0035oc5.1 | Adrenal & Thyroid | ECE2014

Diagnostic and therapeutic outcome in ERCUSYN: Preliminary report in over 1000 patients

Valassi Elena , Santos Alicia , Brue Thierry , Netea-Maier Romana T. , Feelders Richard A. , Yaneva Maria , Tsagarakis Stylianos , Pfeifer Marija , Chanson Philippe , Chabre Olivier , Zopf Kathrin , Toke Judit , Wass John AH , Droste Michael , Maiter Dominique , Dusek Tina , Komerdus Irina , Franz Holger , Lamberts Steven W.J. , Strasburger Christian J.

The European Registry on Cushing’s Syndrome (ERCUSYN) is designed to collect prospective and follow-up data on patients with Cushing’s syndrome (CS) and currently (Sep 2013) includes 1006 patients (804 F, 202 M; mean age (+S.D.) 44.7±13.3 years) from 57 centers in 28 countries.Six hundred and sixty one (66%) had pituitary-dependent CS (PIT-CS), 242 (24%) adrenal-dependent CS (ADR-CS), and 103 (10%) CS from other etiologies, ...